These results led us to conduct a preclinical study based on the inhibition of IL-6 signaling in EAE with an age equivalent to 50 years old in humans, when progressive forms of MS tend to appear, as a potential age-specific treatment for elderly MS patients. The gene discussed is IL6; the disease is myeloid sarcoma.